Therapy
Health
Pharmaceutical

Sarepta Therapeutics

$118.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.59 (2.19%) Today
-$2.34 (-1.94%) After Hours

Why Robinhood?

You can buy or sell SRPT and other stocks, options, ETFs, and crypto commission-free!

About

Sarepta Therapeutics, Inc. Common Stock (DE), also called Sarepta Therapeutics, is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. Read More The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Employees
499
Headquarters
Cambridge, Massachusetts
Founded
1980
Market Cap
8.96B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.26M
High Today
$121.22
Low Today
$118.23
Open Price
$119.31
Volume
238.30K
52 Week High
$176.50
52 Week Low
$90.00

Collections

Therapy
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Technology
US
North America

News

Yahoo Finance48m

Market Weekly Review: Lower Prices Create Buying Opportunities

Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011. After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your Advantage Investors tend to shy away from volatility, which is a word that generally is only mentioned when prices are...

0
Seeking AlphaMay 23

Independent research group finds scant evidence of efficacy for Sarepta's exon-skipping DMD meds

A report prepared for the New England Comparative Effectiveness Public Advisory Council (CEPAC) by the Institute for Clinical and Economic Review (ICER), an independent non-profit research organization that evaluates medical evidence, did not find much evidence supporting the efficacy of Sarepta Therapeutics' (NASDAQ:SRPT) Exondys 51 (eteplirsen), golodirsen or PTC Therapeutics' (NASDAQ:PTCT) Emflaza (deflazacort) in the clinical studies conducted to date.

123
Yahoo FinanceMay 9

When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

228

Earnings

-$1.68
-$1.19
-$0.69
-$0.20
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.